The Development of the Oral Controlled Absorption System (OCAS®): A New Improved Formulation of Tamsulosin
Author:
- Christopher R. ChappleCCChristopher R. Chapple
- 31 October 2005
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 4 (7) , 1-4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy SubjectsEuropean Urology Supplements, 2005
- The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®)European Urology Supplements, 2005
- Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO)European Urology Supplements, 2005
- State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaUrology, 2004
- 230 Comparison of the treatment regimes of new and existing LUTS/BPH patients in 6 European countriesEuropean Urology Supplements, 2004
- AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, 2003
- TamsulosinDrugs, 2002
- Introduction and Concluding RemarksEuropean Urology, 1999
- Relationship Between Gelation Rate of Controlled-release Acetaminophen Tablets Containing Polyethylene Oxide and Colonic Drug Release in DogsPharmaceutical Research, 1996
- The prevalence of Prostatism: A Population-Based Survey of Urinary SymptomsJournal of Urology, 1993